Opinion

Video

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Author(s):

Richard Finn, MD,David James Pinato, MD, MRCP, PhD

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Related Videos
1 expert in this video
1 expert in this video
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
1 expert in this video
1 expert in this video
Richard Kim, MD, Moffitt Cancer Center
Related Content
Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 26th 2024

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Alan P. Venook, MD
November 25th 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Chris Galloway, MD
October 21st 2024

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC